Treatment of raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5‐HT2) receptor

Wiley - Tập 27 Số 2 - Trang 139-146 - 1984
James R. Seibold1,2, Anton H. M. Jageneau1,2
1Division of Rheumatology, Department of Medicine, University of Medicine and Dentistry of New Jersey-Rutgers Medical School, New Brunswick, New Jersey
2the Department of Applied Pharmacology, Janssen Pharmaceutica, Beerse, Belgium.

Tóm tắt

AbstractKetanserin, a selective antagonist of the 5‐HT2 receptor, was evaluated in a 4‐week open pilot trial of 30 patients with Raynaud's phenomenon. Moderate or marked relief was reported in 15 of 18 (83%) patients with systemic sclerosis, whereas only 4 of 12 (33%) patients with Raynaud's phenomenon of other etiology received such benefit (P < 0.01). These subjective ratings were supported by the results of serial digital strain gauge plethysmography during controlled cold challenge. Additional clinical findings suggested that ketanserin therapy facilitated the healing of ischemic digital ulcerations and reduced hand edema in patients with systemic sclerosis. These findings lend support to the hypothesis that serotonin is an important element in the pathogenesis of systemic sclerosis.

Từ khóa


Tài liệu tham khảo

10.1097/00005792-198011000-00001

LeRoy EC, 1981, Scleroderma (systemic sclerosis), Textbook of Rheumatology, 1211

Rodnan GP, 1979, Progressive systemic sclerosis (scleroderma), Arthritis and Allied Conditions, 762

10.1056/NEJM197903293001305

10.1177/000331976001100301

10.1111/j.1365-2133.1976.tb15534.x

10.1177/000331975901000105

10.1016/0024-3205(81)90747-5

Van Nueten JM, 1981, Vascular effects of ketanserin (R 41,468), a novel antagonist of 5‐HT2 serotonergic receptors, J Pharmacol Exp Ther, 218, 217

10.1007/BF01965409

10.7326/0003-4819-97-5-652

10.1002/art.1780240907

10.1002/art.1780251101

10.1002/art.1780230510

Ensink FBM, 1981, The reliability of venous capacity and blood flow determination by plethysmography (JSI‐Periflow) III. Methodical considerations, Noninvasive Methods on Cardiovascular Hemodynamics, 201

Brugmans J, 1981, Venous occlusion plethysmography in the assessment of peripheral vascular changes, Noninvasive Methods on Cardiovascular Hemodynamics, 485

Investigational New Drug Brochure, 1982, Ketanserin: the first pure and selective 5‐HT2‐receptor blocking agent, 102

10.7326/0003-4819-73-2-317

10.1016/0002-9343(69)90044-8

10.1002/art.1780160506

10.1016/0002-9343(76)90410-1

Maricq HR, 1982, Early detection of scleroderma‐spectrum disorders by in vivo capillary microscopy, J Rheumatol, 9, 289

10.1001/archinte.1969.00300110024004

10.1001/archderm.1963.01590240192032

10.7326/0003-4819-89-6-881

10.1002/art.1780241111

10.1378/chest.81.6.695

Alexander EL, 1981, Scleroderma heart disease: evidence for cold‐induced abnormalities of myocardial function and perfusion (abstract), Arthritis Rheum (suppl), 24, S58

10.1126/science.167.3919.898

10.3181/00379727-140-36512

10.1001/archinte.1973.00320100078010

10.1097/00000441-195807000-00001

Brown H, 1977, Serotonin‐producing tumors, Serotonin in Health and Disease, 393

10.3181/00379727-97-23734

10.1038/jid.1963.30

10.1056/NEJM195608092550605

10.1111/j.1365-2133.1977.tb15060.x

Stachow A, 1979, Biogenic amines derived from tryptophan in systemic and cutaneous scleroderma, Acta Dermatovener, 59, 1

10.1056/NEJM197903293001305

10.1056/NEJM198304143081507

10.1001/archinte.132.4.526

Thông tin
Thông tin xuất bản

Wiley

Tập 27 Số 2

139-146

Thông tin tác giả